



Relationship between mandatory warning signs for cannabis use during pregnancy policies and birth outcomes in the Western United States

Sarah C.M. Roberts^{*}, Sarah Raifman, M. Antonia Biggs

Advancing New Standards in Reproductive Health, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, 1330 Broadway, Suite 1100, Oakland, CA 94612, United States of America

ARTICLE INFO

Keywords:
Policy
Cannabis
Pregnancy

ABSTRACT

As U.S. states legalize recreational cannabis, some enact policies requiring Mandatory Warning Signs for cannabis during pregnancy (MWS-cannabis). While previous research has found MWS for alcohol during pregnancy (MWS-alcohol) associated with increases in adverse birth outcomes, research has not examined effects of MWS-cannabis. This study uses Vital Statistics birth certificate data from June 2015 – June 2017 in seven western states and policy data from NIAAA's Alcohol Policy Information System and takes advantage of the quasi-experiment created by Washington State's enactment of MWS-cannabis in June 2016, while nearby states did not. Outcomes are birthweight, low birthweight, gestation, and preterm birth. Analyses use a Difference-in-Difference approach and compare changes in outcomes in Washington to nearby states in the process of legalizing recreational cannabis (Alaska, California, Nevada) and, as a secondary analysis, nearby states continuing to criminalize recreational cannabis (Idaho, Montana, Wyoming). Birthweight was -7.03 g lower (95% CI -10.06 , -4.00) and low birthweight 0.3% higher (95% CI 0.0, 0.6) when pregnant people were exposed to MWS-cannabis than when pregnant people were not exposed to MWS-cannabis, both statistically significant ($p = 0.005$ and $p = 0.041$). Patterns for gestation, -0.014 weeks earlier (95% CI -0.038 , 0.010) and preterm birth 0.2% higher (95% CI -0.2 , 0.7), were similar, although not statistically significant ($p = 0.168$ and 0.202). The direction of findings was similar in secondary analyses, although statistical significance varied. Similar to MWS-alcohol, enacting MWS-cannabis is associated with an increase in adverse birth outcomes. The idea that MWS-cannabis provide a public health benefit is not evidence-based.

1. Introduction

In 2012, Colorado and Washington State became the first states to legalize cannabis for recreational use in the United States (NIAAA, 2020). Currently, 15 states have legalized cannabis for recreational use (NIAAA, 2020). Importantly, legalizing cannabis has contributed to reductions in arrests and incarceration, particularly among adults (Plunk et al., 2019). While there were early hopes that legalizing cannabis would result in reductions in other substance use, these benefits have not been substantiated (Pacula et al., 2022; Neilson et al., 2021). Research, instead, has identified potential health risks associated with cannabis legalization (Hinckley et al., 2022; Masonbrink et al., 2021). Thus, more attention is now being paid to health-related regulations (Neeley and Richardson Jr., 2022), such as regulations used for tobacco and alcohol—taxation, potency of products, stringency of retail sales licensing, and lower-risk use guidelines—(NIAAA, 2020; Fischer et al., 2022) as

strategies to reduce health harms related to cannabis use.

Possible adverse health effects of pregnant people's cannabis use is one area public health authorities are concerned about in the context of legalization (Wang et al., 2022; Agrawal et al., 2019). Evidence indicates there are some adverse health effects associated with cannabis use during pregnancy, including increased risks of low birthweight and adverse childhood psychological outcomes (Paul et al., 2020; National Academies of Sciences, 2017; Nguyen and Harley, 2022). These effects have been documented particularly among people who continue to use cannabis after discovering pregnancy and people who use both cannabis and tobacco during pregnancy (Paul et al., 2020; Nguyen and Harley, 2022). Research suggests pregnant people's cannabis use is increasing, although research is mixed as to whether this increase is due to legalization (Agrawal et al., 2019; Bayrampour and Asim, 2021; Lee et al., 2022; Young-Wolff et al., 2017; Young-Wolff et al., 2021; Gnofam et al., 2020).

^{*} Corresponding author.

E-mail address: sarah.roberts@ucsf.edu (S.C.M. Roberts).

<https://doi.org/10.1016/j.ypmed.2022.107297>

Received 14 July 2022; Received in revised form 1 September 2022; Accepted 4 October 2022

Available online 10 October 2022

0091-7435/© 2022 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

In response to the concern about possible adverse health effects of pregnant people's cannabis use, five states have enacted policies requiring posting point-of-sale Mandatory Warning Signs related to cannabis use during pregnancy (MWS-cannabis) in places where cannabis is sold (NIAAA, 2021). MWS-cannabis policies provide pregnancy-specific warnings about cannabis use to increase pregnant people's awareness about the risks of use and thus lead them to stop using during pregnancy. However, the idea that MWS reduce substance use is not well-supported by existing evidence. Specifically, despite point-of-sale Mandatory Warning Signs for alcohol use during pregnancy (MWS-alcohol) going into effect in >15 states by the mid-1990s and currently in effect in 25 states, alcohol use during pregnancy has remained roughly steady since the mid-1990s (Centers for Disease Control and Prevention, 1997; Centers for Disease Control and Prevention, 2002; Centers for Disease Control and Prevention, 2009; Zhao et al., 2012; Denny et al., 2019; Hasin et al., 2019). One national study found that MWS-alcohol was associated with lower self-reported alcohol consumption (Roberts et al., 2019). A study about pregnancy-specific alcohol warning messages on bottle labels found that these labels were associated with small decreases in alcohol consumption during pregnancy among lower risk, but not higher risk, drinkers (Hankin et al., 1993; Hankin et al., 1996). Research on effects of state-level pregnancy-specific substance use policies in general indicates that such policies typically do not achieve intended purposes of reducing substance use during pregnancy; instead, many appear to increase adverse health outcomes and reduce prenatal care and substance use disorder treatment utilization (Faherty et al., 2019; Atkins and Durrance, 2020; Subbaraman and Roberts, 2019; Subbaraman et al., 2018; Tabatabaepour et al., 2022). Research on MWS-alcohol is consistent with this larger literature; the research finds that enacting MWS-alcohol is associated with increases in low birthweight and preterm births, as well as decreases in prenatal care use (Subbaraman and Roberts, 2019; Subbaraman et al., 2018). These findings suggest that MWS policies, like other pregnancy-specific substance use policies, may increase pregnant people's fears of judgment and punishment and thus lead them to avoid prenatal care (Roberts and Nuru-Jeter, 2010; Roberts and Pies, 2011). An important and policy-relevant research question is whether the findings related to MWS-alcohol apply to MWS-cannabis, a question this study seeks to answer.

2. Methods

2.1. Overarching study design

This study used individual-level birth data from 2015 to 2017 Natality Birth Data (Vital Statistics) and state-level policy data from the Alcohol Policy Information System (APIS), original legal research, and other secondary sources. The University of California, San Francisco, Institutional Review Board, considered this research exempt. It sought to examine the relationship between enacting MWS-cannabis and adverse birth outcomes. To do so, we took advantage of a quasi-experiment where Washington State enacted MWS-cannabis and nearby states did not. We used a Difference-in-Differences framework to compare changes in birth outcomes in Washington State to changes in birth outcomes in comparison states before and after Washington State enacted MWS-cannabis in June 2016. This study is one component of a larger project to understand the relationship between MWS-cannabis and a range of outcomes, including birth outcomes and beliefs about and attitudes towards pregnant people's cannabis use. The larger project has a community advisory board comprised of people with relevant lived experience and who have provided insight into interpreting the findings in this manuscript.

2.2. Data source(s)

We relied on these data sources:

1. Vital statistics birth certificate data to measure birth outcomes (birthweight, low birthweight, gestation, and preterm birth) and individual-level control variables. We relied on restricted use individual-level Vital Statistics data for U.S. births of people who were estimated to have become pregnant between June 2015 and June 2017 (one year before and after MWS-cannabis was enacted in Washington State) from the United States National Center for Health Statistics. Consistent with other assessments of trends in adverse birth outcomes over time (Osterman et al., 2022), we restricted analyses to singleton births (97% of births) because multiple births have different birthweight and gestation curves as well as higher likelihood of adverse birth outcomes (Powers and Kiely, 1994; Alexander et al., 1998).
2. NIAAA's APIS and original legal research for MWS-cannabis (our primary exposure variable) and for recreational cannabis policy. State-level MWS-cannabis data and recreational cannabis legalization data were obtained from APIS (NIAAA, 2020; NIAAA, 2021) as well as original legal research conducted by APIS policy coders using Westlaw and HeinOnline, online legal databases. The legal research process has been described previously (Roberts et al., 2017).
3. U.S. Bureau of Labor Statistics to obtain state-level unemployment data, to serve as a state-level control variable.

We merged policy data with individual-level vital statistics data based on the month/year the person became pregnant.

2.3. State selection

As an intervention state, we sought to identify a state that had enacted MWS-cannabis long enough ago that outcome data would be available and long enough after legalizing recreational cannabis for the effects of those policies to be distinguishable. We identified five states with MWS-cannabis. We chose Washington State as the intervention state because it legalized recreational cannabis in 2012 and enacted MWS-cannabis in June 2016 (NIAAA, 2020; NIAAA, 2021). The other four states (Arizona, Colorado, Illinois, Oregon) that had enacted MWS-cannabis (as of January 1, 2021) (NIAAA, 2021) were not suitable for inclusion for several reasons: Colorado and Illinois enacted MWS-cannabis in 2020 or 2021, too recent for Vital Statistics birth certificate data to be available and their outcomes may be confounded by the COVID-19 pandemic; Arizona enacted MWS-cannabis in 2017, but did not legalize recreational cannabis until 2020 (NIAAA, 2020; NIAAA, 2021); and Oregon enacted MWS-cannabis less than three months after legalizing recreational cannabis in 2015 (NIAAA, 2020; NIAAA, 2021), which meant it would not be possible to distinguish effects of MWS-cannabis from effects of legalizing recreational cannabis.

To identify comparison states, we considered states that were also in the Western U.S. and were in the process of legalizing recreational cannabis (but not at the same time as Washington enacted MWS-cannabis) or that continued to criminalize recreational cannabis throughout the study period. We selected comparison states that met the parallel trends assumption, a key assumption of Difference-in-Differences analysis. We first considered Colorado, as it legalized cannabis for recreational purposes around the same time as Washington (in 2012). However, the parallel trends assumption was violated for all outcomes considered. Aside from Colorado, three nearby states were in the process of legalizing recreational cannabis (Alaska, California, and Nevada) and three nearby states continued to criminalize recreational cannabis throughout the study period (Idaho, Montana, and Wyoming). For these states and Washington, we confirmed that no other major policy changes plausibly related to our outcomes of interest, i.e. tobacco taxes (Centers for Disease Control and Prevention, 2022a), other pregnancy-specific alcohol/drug policies (NIAAA, 2021), occurred at the same time as the MWS-cannabis policy change that is the prime exposure of interest. Table 1 lists the MWS-cannabis enactment date plus legalization of recreational cannabis date for each included state. We

Table 1

Study states and MWS-cannabis and recreational cannabis legalization and enactment dates.

	MWS-cannabis law and enactment date	Legalize recreational cannabis and date of legalization enactment
Washington	6/18/2016	Yes, 12/6/2012
Alaska	None	Yes, 2/24/2015
California	None	Yes, 11/9/2016
Nevada	None	Yes, 1/1/2017
Idaho	None	No
Montana	None	Yes, 1/1/2021
Wyoming	None	No

Data source: Alcohol Policy Information System: (NIAAA, 2020; NIAAA, 2021).

selected the group of states that met the parallel trends assumption for all outcomes (Alaska, California, Nevada, “primary comparison states”, See Table 3 and Fig. 1) to serve as our primary comparison, and the group of states that met the parallel trends assumption for only some outcomes (Idaho, Montana, Wyoming, “secondary comparison states”, See Table 4) to serve as a secondary comparison.

2.4. Variables

The main *exposure* was MWS-cannabis, coded as 1 for all babies born in Washington to people who became pregnant between June 2016–June 2017 (when MWS-cannabis was in effect) and 0 for babies born in Washington to people who became pregnant between June 2015–May 2016 and all people who became pregnant between June 2015–June 2017 in other states (when MWS-cannabis was not in effect). MWS-cannabis policies require that warning signs about possible harms from cannabis use during pregnancy be posted in licensed retail settings where cannabis is sold (NIAAA, 2021). *Outcomes* included birthweight (continuous, in grams), low birthweight (dichotomous, born less versus at or more than 2500 g) (Centers for Disease Control and Prevention, 2022b), gestation (continuous, weeks), and preterm birth (dichotomous, born before versus at or after 37 weeks gestation) (Behrman and Stith Butler, 2007). We excluded cases with implausible birthweight (<299 and > 4456 g) (Talge et al., 2014) and cases with implausible gestation (<21 and > 45 weeks).

Individual-level controls included maternal: parity (categorical: nulliparous, 1 previous live birth, 2+ previous live births), age (categorical: <19; 20–29; 30–39; 40 or older), marital status (dichotomous); education (categorical: less than high school, high school equivalent, more than high school), race/ethnicity (categorical: white, non-Hispanic; Black, non-Hispanic; Hispanic of any race; Asian/Pacific Islander, non-Hispanic; other/missing, non-Hispanic), nativity (dichotomous, U.S. born, non-U.S. born), and tobacco (dichotomous, of use during pregnancy). One state, California, ceased collecting marital status in 2017. Methods for handling this missing covariate are described below. *State-level controls* included timing of cannabis legalization (dichotomous, 1 for months in which recreational cannabis was legal and 0 for months in which recreational cannabis was not legal) and unemployment (continuous). *State* was the pregnant person's state of residence at the time of birth and *month* was the estimated month and year the person became pregnant.

2.5. Data analysis

Our overall approach to data analysis was a Difference-in-Differences analysis. We compare differences in changes in birth outcomes from before to after enactment of MWS-cannabis in Washington State to our primary comparison states (Alaska, California, Nevada) and, as a secondary analysis, to our secondary comparison states (Idaho, Montana, Wyoming). We conducted a sensitivity analysis that used all six comparison states. We also conducted sensitivity analyses, using month of birth rather than estimated month people became pregnant.

Difference-in-Differences models included individual- and state-level controls, as well as fixed effects for month and state, and accounted for clustering of standard errors according to state of residence and month of conception. Individual-controls were selected based on conceptual importance and on examinations of compositional changes of the sample [See Supplement 1]. Analyses were conducted in Stata 17.0. We tested the parallel trends assumption using post-estimation commands and graphical visualization.

There was minimal missing data for individual-level controls, with most variables missing <1%; for these variables, we used casewise deletion. The only individual-level control variable missing >5% was marital status, which was missing for all of California beginning in 2017, when California stopped including those data in the Vital Statistics records. For models that included California, we first excluded marital status as a covariate and then used multiple imputation. Findings did not differ between analyses that excluded marital status as a covariate and the multiple imputation models that included marital status in direction or size of effect and did not differ in statistical significance for three of the four outcomes. We thus present simpler models that exclude marital status as a covariate.

3. Results

3.1. Sample description

Table 2 includes information about total births in Washington (MWS-cannabis state) as well as primary and secondary comparison states. In Washington from before to after MWS-cannabis, mean birthweight decreased (3355 to 3347 g), the proportion of low birthweight and preterm births increased (5.1% to 5.3%; 8.0% to 8.2%, respectively), while gestation remained relatively flat. Birthweight also decreased in comparison states, while the percent low birthweight increased slightly in primary comparison states but not secondary comparison states, and the percent preterm births increased in all comparison states. Gestation remained flat in all comparison states.

3.2. Primary comparisons (Washington compared to Alaska, California, Nevada)

The change in birthweight from before to after Washington enacted MWS-cannabis was 7.03 g less (95% CI -10.06, -4.00) and the change in low birthweight was 0.3% greater (95% CI 0.0, 0.6) among people exposed to MWS-cannabis than people not exposed to MWS-cannabis, both statistically significant ($p = 0.005$ and $p = 0.041$). This translates to 269 babies born low birthweight in Washington June 2016–June 2017 related to the MWS-cannabis policy. Patterns for gestation, -0.014 weeks earlier (95% CI -0.038, 0.010), and preterm birth, 0.2% greater (95% CI -0.2, 0.7), were similar, although not statistically significant ($p = 0.168$ and 0.202) at a $p < 0.05$ level [See Table 3 and Fig. 1].

3.3. Secondary comparisons (Washington compared to Idaho, Montana, Wyoming)

The direction of findings was similar when comparing Washington to secondary comparison states, although statistical significance of findings varied, as did whether comparisons met the parallel trends assumptions [See Table 4].

3.4. Sensitivity analyses

In sensitivity analyses using birth month rather than estimated month people became pregnant, there was no substantive difference in findings, with the exceptions of the finding for low birthweight no longer being statistically significant in the primary comparisons and the finding for gestation no longer being statistically significant in the




Fig. 1. Trends in birth outcomes in Washington (MWS-cannabis state) and primary comparison states (Alaska, California, Nevada).





Fig. 1. (continued).

Table 2

Births and birth outcomes in Washington State and Comparison states.

	Births N ^a		Birthweight mean (sd)		Low birthweight % (n)		Gestation mean (sd)		Preterm birth % (n)	
	Pre-	Post-	Pre-	Post-	Pre-	Post-	Pre-	Post-	Pre-	Post-
Washington	85,588	89,698	3355 (523)	3347 (527)	5.1 (4351)	5.3 (4760)	39.0 (2.1)	39.0 (2.2)	8.0 (7017)	8.2 (7503)
Alaska, California, and Nevada	510,714	530,538	3299 (518)	3297 (519)	5.5 (28,033)	5.6 (29,559)	38.8 (2.0)	38.8 (2.0)	7.6 (38,524)	7.7 (40,801)
Idaho, Montana, Wyoming	40,279	42,164	3294 (520)	3289 (520)	6.0 (2409)	6.0 (2544)	38.8 (2.2)	38.8 (2.2)	9.1 (3654)	9.6 (4017)

^a These are the numbers of births included in birthweight models. Note that: 0.014% (17,699) of births were excluded from Washington, Alaska, California, and Nevada models due to having an implausible birthweight. An additional 0.002% (2287) of births were excluded from Washington, Alaska, California, and Nevada models for gestation due to having an implausible gestation.

Table 3Relationship between enacting MWS-cannabis (in Washington State) and birth outcomes^a.

	Birthweight (grams)			Low birthweight (<2500 g)			Gestation (weeks)			Preterm birth (<37 weeks)		
	N = 1,154,161			N = 1,154,161			N = 1,151,980			N = 1,151,980		
	Coef	95% CI	p-value	Coef	95% CI	p-value	Coef	95% CI	p-value	Coef	95% CI	p-value
MWS-cannabis	-7.029	-10.055, -4.003	0.005	0.003	0.000, 0.006	0.041	-0.014	-0.038, 0.010	0.168	0.002	-0.002, 0.007	0.202
Parallel trends test			0.402			0.863			0.306			0.197

Bold indicates where finding is statistically significant and does not violate parallel trends assumption ($p < 0.05$ indicates a violation of the parallel trends assumption). Models control for individual-level: parity, age, education, race/ethnicity, nativity, and tobacco; state-level: recreational cannabis legalization and unemployment; included fixed effects for state and month and cluster standard errors by state and month.

^a Washington, Alaska, California, Nevada.

Table 4Relationship between enacting MWS-cannabis (in Washington State) and birth outcomes with alternative comparison states^a.

	Birthweight			Low birthweight			Gestation			Preterm birth		
	Coef	95% CI	p-value	Coef	95% CI	p-value	Coef	95% CI	p-value	Coef	95% CI	p-value
Washington compared to secondary comparison states ^a	N = 249,741			N = 249,741			N = 248,665			N = 248,665		
MWS	-3.469	-16.957, 10.019	0.473	0.003	-0.003, 0.008	0.218	-0.018	-0.037, -0.002	0.063	-0.001	-0.004, 0.001	0.122
Parallel trends test			0.567			0.035 ^c			0.187			0.033 ^c
Washington compared to primary and secondary comparison states ^b	N = 1,235,386			N = 1,235,386			N = 1,232,877			N = 1,232,877		
	-4.131	-7.728, -0.534	0.031	0.002	0.000, 0.003	0.036	-0.004	-0.018, 0.009	0.461	0.000	-0.003, 0.003	0.764
Parallel trends test			0.678			0.295			0.060			0.001 ^c

Bold indicates where finding is statistically significant and does not violate parallel trends assumption ($p < 0.05$ indicates a violation of the parallel trends assumption). Models control for individual-level: parity, age, education, race/ethnicity, marital status (for comparison with secondary comparison states only), nativity, and tobacco; state-level: recreational cannabis legalization and unemployment; included fixed effects for state and month and cluster standard errors by state and month.

^a Washington, Idaho, Montana, Wyoming.

^b Washington, Alaska, California, Idaho, Montana, Nevada, Wyoming.

^c Violates parallel trends assumption.

secondary comparisons.

4. Discussion

This study found that enacting MWS for cannabis use during pregnancy was associated with increased adverse birth outcomes, particularly lower birthweights and higher proportions of babies born low birthweight. While there was also a decrease in weeks gestation and an increase in the proportion of babies born preterm, these changes were not statistically significant at a $p < 0.05$ level. These findings are similar to previous research about MWS for alcohol use during pregnancy (Subbaraman and Roberts, 2019).

While, at face value, MWS for cannabis during pregnancy is assumed

by policymakers to have public health value, our findings do not support this assumption. Extant literature and feedback from this study's community advisory board provides explanations for the pathway through which MWS-cannabis could contribute to adverse birth outcomes. Research examining MWS-alcohol finds MWS-alcohol associated with decreased prenatal care use, suggesting that such warning signs may deter people from care, which might contribute to increased risk for adverse birth outcomes (Subbaraman et al., 2018). Qualitative research about barriers to prenatal care for pregnant people who use alcohol and/or drugs has found that fear of having already irreversibly harmed the baby and fear of being reported to Child Protective Services (CPS) related to substance use during pregnancy are reasons that pregnant people physically avoid and emotionally disengage from prenatal care

(Roberts and Nuru-Jeter, 2010; Roberts and Pies, 2011). While many people who use cannabis during pregnancy consider cannabis use during pregnancy to be safe (Macario and Thomas, 2022; McKenzie et al., 2022; Satti et al., 2022), it is possible that MWS-cannabis could increase some people's fears that they may have already irreversibly harmed their baby by using cannabis before they found out they were pregnant. This could make them believe that reducing or stopping later in pregnancy will not make a difference. It could also lead to people using either prescribed alternatives or other means of self-treatment that may increase risks of these outcomes. Relationships of MWS-cannabis to changes in cannabis use and other substances (including prescribed medications) should be explored in future research. Importantly though, similar to the legality of alcohol use, legalization of recreational cannabis has not removed requirements related to health care providers reporting birthing people who use cannabis to CPS; and pregnant people in states with legalized recreational cannabis report that this fear of health care providers reporting to CPS remains a barrier to prenatal care, even after legalization (Woodruff et al., 2021; Barbosa-Leiker et al., 2020). Pregnant and birthing people's drug use is considered reportable to CPS in Washington State (Morgridge Institute for Research, 2022). Further, the Washington State Department of Health published guidelines in 2015 stating that all positive urine toxicology tests at the time of delivery should be reported to CPS (Washington State Department of Health, 2022); they do not exclude cannabis from this guidance. Research conducted in Washington State found that health care providers had been commonly reporting cannabis use during pregnancy to CPS through 2013 (Rebbe et al., 2019). In the context of this threat of punishment, pregnant people may perceive a sign with a government warning on it as a threat of CPS involvement or punishment, something to be explored in future research.

These findings are also consistent with the broader literature on effects of pregnancy-specific alcohol and drug policies. While long-standing scholarly literature and advocacy efforts have separated out alcohol-focused from drug-focused pregnancy policies, a study published in 2018 found that, with the exception of MWS policies, most pregnancy-specific policies cover both (Thomas et al., 2018). Thus, with the exception of findings for MWS for alcohol policies, other findings from the literature about pregnancy-specific alcohol policies can generally be interpreted as applying to both alcohol and drugs and vice versa. This study suggests that the findings about the relationship between MWS-alcohol and birth outcomes (Subbaraman et al., 2018) also appear to generalize to cannabis.

Policymakers and public health professionals concerned about increases in pregnant people's use of cannabis and possible health effects of an increase may wonder about the implications of these findings for policy and public health action. First, it is worth noting that substance (including cannabis) use during pregnancy is not typically new use in pregnancy, but rather use continued from before people became pregnant (Satti et al., 2022; Tran et al., 2015). Work to understand people's reasons for continuing to use cannabis while they are pregnant and developing resources and supports that are relevant for people's experiences may be more important for their health and the health of their pregnancy than MWS-cannabis. Second, recreational cannabis legalization does not remove the threat of punishment for pregnant people who use cannabis; as long as that threat is in place, it seems reasonable to assume that MWS for cannabis may have unintended consequences. Third, rather than looking to existing pregnancy-specific substance use policies for legal substances (such as alcohol and tobacco), it is important to remember that the origin of most pregnancy-specific alcohol and drug policies is in the War on Drugs and that the pregnancy-specific policies generally considered more supportive (e.g. priority treatment) appear to have emerged from advocacy responses to War on Drugs-inspired punitive policies (Roberts et al., 2021). Instead, policymakers and public health professionals should bring pregnant people who use cannabis in to the policymaking process to identify the information and supports relevant for their lives.

This study has some limitations. Specifically, we examined effects of a MWS-cannabis policy change in a single state. While internal validity of the study is high, given the study design, applying findings to other states should be done with attention to factors that may differ between Washington and other states of interest. That the finding was consistent with research about 40 years of MWS-alcohol in all U.S. states (Subbaraman et al., 2018) suggest the findings may generalize, though. Should more states enact MWS-cannabis and these policy changes occur long enough before/after legalization and the first two years of the COVID-19 pandemic, additional research examining impacts of these policies would be warranted. Further, the outcome data were not collected for research purposes. While there are few measurement changes on the birth certificate during our two-year study period, a possibly relevant variable (marital status) was no longer included in the data beginning in 2017. However, we did not find differences across our two approaches to handling these missing data. The data also do not include relevant mediators, such as data on knowledge about cannabis use during pregnancy or data on cannabis use, which may be important to explore in future research.

5. Conclusions

Similar to findings for MWS for alcohol use during pregnancy, enacting MWS for cannabis use during pregnancy is associated with increases in adverse birth outcomes. The idea that MWS for cannabis use during pregnancy provide a public health benefit is not based in evidence.

Funding

Research reported in this publication was supported by the California Department of Cannabis Control, Grant agreement 65328 and the National Institute On Alcohol Abuse And Alcoholism of the National Institutes of Health under Award Number R01AA023267. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The funders had no role in study design; collection, analysis, and interpretation of data; writing of the manuscript; or the decision to submit the manuscript for publication. The authors have no conflicts of interest to disclose.

CRedit authorship contribution statement

Sarah C.M. Roberts: Conceptualization, Methodology, Formal analysis, Writing – original draft, Visualization, Funding acquisition. **Sarah Raifman:** Methodology, Writing – review & editing. **M. Antonia Biggs:** Methodology, Writing – review & editing.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Data availability

The authors do not have permission to share data.

Acknowledgments

The authors thank Meenakshi Subbaraman, PhD; Nancy Berglas, DrPH; Sue Thomas, PhD; and Claudia Zaugg, MPH for support with database creation and our Community Advisory Board for input interpreting findings.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.ypmed.2022.107297>.

References

- Agrawal, A., Rogers, C.E., Lessov-Schlaggar, C.N., Carter, E.B., Lenz, S.N., Grucza, R.A., 2019. Alcohol, cigarette, and Cannabis use between 2002 and 2016 in pregnant women from a nationally representative sample. *JAMA Pediatrics*. 173 (1), 95–96.
- Alexander, G.R., Kogan, M., Martin, J., Papiernik, E., 1998. What are the fetal growth patterns of singletons, twins, and triplets in the United States? *Clin Obstet Gynecol*. 41 (1), 114–125.
- Atkins, D.N., Durrance, C.P., 2020. State policies that treat prenatal substance use as child abuse or neglect fail to achieve their intended goals. *Health Affairs*. 39 (5), 756–763.
- Barbosa-Leiker, C., Burduli, E., Smith, C.L., Brooks, O., Orr, M., Gartstein, M., 2020. Daily Cannabis use during pregnancy and postpartum in a state with legalized recreational Cannabis. *J Addict Med*. 14 (6), 467–474.
- Bayrampour, H., Asim, A., 2021. Cannabis use during the pre-conception period and pregnancy after legalization. *J Obstet Gynaecol Can*. 43 (6), 740–745.
- Behrman, R.E., Stith Butler, A. (Eds.), 2007. *Preterm Birth: Causes, Consequences, and Prevention*, 2010/07/30 ed. Institute of Medicine, National Academies Press, Washington, DC.
- Centers for Disease Control & Prevention, 1997. Alcohol consumption among pregnant and childbearing-aged women—United States, 1991 and 1995. *MMWR Morb Mortal Wkly Rep*. 46 (16), 346–350.
- Centers for Disease Control & Prevention, 2002. Alcohol use among women of childbearing age—United States, 1991–1999. *MMWR Morb Mortal Wkly Rep*. 51 (13), 273–276.
- Centers for Disease Control & Prevention, 2009. Alcohol use among pregnant and nonpregnant women of childbearing age - United States, 1991–2005. *MMWR Morb Mortal Wkly Rep*. 58 (19), 529–532.
- Centers for Disease Control & Prevention, 2022a. The tax burden on tobacco, 1970–2019. <https://chronicdata.cdc.gov/Policy/The-Tax-Burden-on-Tobacco-1970-2019/7nwe-3aj9>.
- Centers for Disease Control & Prevention, 2022b. Birthweight and Gestation. <http://www.cdc.gov/nchs/fastats/birthwt.htm>. Accessed May 10, 2010.
- Denny, C.H., Acero, C.S., Naimi, T.S., Kim, S.Y., 2019. Consumption of alcohol beverages and binge drinking among pregnant women aged 18–44 years - United States, 2015–2017. *MMWR Morb Mortal Wkly Rep*. 68 (16), 365–368.
- Faherty, L.J., Kranz, A.M., Russell-Fritch, J., Patrick, S.W., Cantor, J., Stein, B.D., 2019. Association of punitive and reporting state policies related to substance use in pregnancy with rates of Neonatal Abstinence Syndrome. *JAMA Netw Open*. 2 (11), e1914078.
- Fischer, B., Robinson, T., Bullen, C., et al., 2022. Lower-risk Cannabis use guidelines (LRCUG) for reducing health harms from non-medical cannabis use: a comprehensive evidence and recommendations update. *Int J Drug Policy*. 99, 103381.
- Gnofam, M., Allhouse, A.A., Stickrath, E.H., Metz, T.D., 2020. Impact of Marijuana legalization on prevalence of maternal Marijuana use and perinatal outcomes. *Am J Perinatol*. 37 (1), 49–65.
- Hankin, J.R., Sloan, J.J., Firestone, I.J., Ager, J.W., Sokol, R.J., Martier, S.S., 1993. A time series analysis of the impact of the alcohol warning label on antenatal drinking. *Alcohol Clin Exp Res*. 17 (2), 284–289.
- Hankin, J.R., Firestone, I.J., Sloan, J.J., Ager, J.W., Sokol, R.J., Martier, S.S., 1996. Heeding the alcoholic beverage warning label during pregnancy: multiparae versus nulliparae. *J Stud Alcohol*. 57 (2), 171–177.
- Hasin, D.S., Shmulewitz, D., Keyes, K., 2019. Alcohol use and binge drinking among U.S. men, pregnant and non-pregnant women ages 18–44: 2002–2017. *Drug Alcohol Depend*. 205, 107590.
- Hinckley, J., Bhatia, D., Ellingson, J., Molinero, K., Hopfer, C., 2022. The impact of recreational cannabis legalization on youth: the Colorado experience. *Eur Child Adolesc Psychiatry*. <https://doi.org/10.1007/s00787-022-01981-0>, 2022. PMID: 35428897.
- Lee, E., Pluym, I.D., Wong, D., Kwan, L., Varma, V., Rao, R., 2022. The impact of state legalization on rates of marijuana use in pregnancy in a universal drug screening population. *J Matern Fetal Neonatal Med*. 35 (9), 1660–1667.
- Macario, E., Thomas, R.M., 2022. Reasons Washington State women use Marijuana during pregnancy/breastfeeding, their trusted information sources, and communication strategies for informed decision-making. *J Perinat Neonatal Nurs*. 36 (3), 243–255.
- Masonbrink, A.R., Richardson, T., Hall, M., Catley, D., Wilson, K., 2021. Trends in adolescent Cannabis-related hospitalizations by state legalization laws, 2008–2019. *J Adolesc Health*. 69 (6), 999–1005.
- McKenzie, L.B., Keim, S.A., Klebanoff, M.A., 2022. Risk perceptions about cannabis use and receipt of health-related information during pregnancy. *Am J Health Promot*. <https://doi.org/10.1177/08901171221099496>. PMID: 35512115, Epub ahead of print.
- Morgridge Institute for Research, 2022. Infants with Prenatal Substance Exposure. <https://morgridge.org/research/bioethics/prenatal-substance-exposure/>. Accessed May 20, 2022.
- National Academies of Sciences, 2017. The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. National Academies Press, Washington (DC).
- Neeley, G.W., Richardson Jr., L.E., 2022. Marijuana policy bundles in the American States over time and their impact on the use of Marijuana and other drugs. *Eval Rev*. 46 (2), 165–199.
- Neilson, L.M., Swift, C., Swart, E.C.S., et al., 2021. Impact of Marijuana legalization on opioid utilization in patients diagnosed with pain. *J Gen Intern Med*. 36 (11), 3417–3422.
- Nguyen, V.H., Harley, K.G., 2022. Prenatal Cannabis use and infant birth outcomes in the pregnancy risk assessment monitoring system. *J Pediatr*. 240, 87–93.
- NIAAA, 2020. Alcohol Policy Information System. Recreational Use of Cannabis: Volume 1. <https://alcoholpolicy.niaaa.nih.gov/cannabis-policy-topics/recreational-use-of-cannabis-volume-1/104>.
- NIAAA, 2021. Alcohol Policy Information System. <http://www.alcoholpolicy.niaaa.nih.gov/>. Accessed June 8, 2021.
- Osterman, M.J.K., Hamilton, B.E., Martin, J.A., Driscoll, A.K., Valenzuela, C.P., 2022. Births: final data for 2020. *Natl Vital Stat Rep*. 70 (17).
- Pacula, R.L., Smart, R., Lira, M.C., Pessar, S.C., Blanchette, J.G., Naimi, T.S., 2022. Relationships of Cannabis policy liberalization with alcohol use and co-use with Cannabis: a narrative review. *Alcohol Res*. 42 (1), 06.
- Paul, S.E., Hatoum, A.S., Fine, J.D., et al., 2020. Associations between prenatal cannabis exposure and childhood outcomes: results from the ABCD study. *JAMA Psychiatry*. 78 (1), 64–76.
- Plunk, A.D., Peglow, S.L., Harrell, P.T., Grucza, R.A., 2019. Youth and adult arrests for cannabis possession after decriminalization and legalization of Cannabis. *JAMA Pediatrics*. 173 (8), 763–769.
- Powers, W.F., Kiely, J.L., 1994. The risks confronting twins: a national perspective. *Am J Obstet Gynecol*. 170 (2), 456–461.
- Rebbe, R., Mienko, J.A., Brown, E., Rowhani-Rahbar, A., 2019. Child protection reports and removals of infants diagnosed with prenatal substance exposure. *Child Abuse Negl*. 88, 28–36.
- Roberts, S.C.M., Nuru-Jeter, A., 2010. Women's perspectives on screening for alcohol and drug use in prenatal care. *Womens Health Issues*. 20 (3), 193–200.
- Roberts, S.C.M., Pies, C., 2011. Complex calculations: how drug use during pregnancy becomes a barrier to prenatal care. *Matern Child Health J*. 15 (3), 333–341.
- Roberts, S.C.M., Thomas, S., Treffers, R., Drabble, L., 2017. Forty years of state alcohol and pregnancy policies in the USA: best practices for public health or efforts to restrict women's reproductive rights? *Alcohol Alcohol*. 52 (6), 715–721.
- Roberts, S.C.M., Mericle, A.A., Subbaraman, M.S., et al., 2019. State policies targeting alcohol use during pregnancy and alcohol use among pregnant women 1985–2016: evidence from the behavioral risk factor surveillance system. *Womens Health Issues*. 29 (3), 213–221.
- Roberts, S.C.M., Thompson, T.A., Taylor, K.J., 2021. Dismantling the legacy of failed policy approaches to pregnant people's use of alcohol and drugs. *Int Rev Psychiatry*. 1–12.
- Satti, M.A., Reed, E.G., Wenker, E.S., et al., 2022. Factors that shape pregnant women's perceptions regarding the safety of cannabis use during pregnancy. *J Cannabis Res*. 4 (1), 16.
- Subbaraman, M.S., Roberts, S.C.M., 2019. Costs associated with policies regarding alcohol use during pregnancy: results from 1972–2015 Vital Statistics. *PLoS One*. 14 (5), e0215670.
- Subbaraman, M.S., Thomas, S., Treffers, R., et al., 2018. Associations between state-level policies regarding alcohol use among pregnant women, adverse birth outcomes, and prenatal care utilization: results from 1972 to 2013 Vital Statistics. *Alcohol Clin Exp Res*. 42 (8), 1511–1517.
- Tabatabaee, N., Morgan, J.R., Jalali, A., Kapadia, S.N., Meinhofer, A., 2022. Impact of prenatal substance use policies on commercially insured pregnant females with opioid use disorder. *J Subst Abuse Treat*. 140, 108800. <https://doi.org/10.1016/j.jsat.2022.108800>. PMID: 35577664.
- Talge, N.M., Mudd, L.M., Sikorskii, A., Basso, O., 2014. United States birth weight reference corrected for implausible gestational age estimates. *Pediatrics*. 133 (5), 844–853.
- Thomas, S., Treffers, R., Berglas, N.F., Drabble, L., Roberts, S.C.M., 2018. Drug use during pregnancy policies in the United States from 1970 to 2016. *Contemp Drug Probl*. 45 (4), 441–459.
- Tran, N.T., Najman, J.M., Hayatbakhsh, R., 2015. Predictors of maternal drinking trajectories before and after pregnancy: evidence from a longitudinal study. *Aust N Z J Obstet Gynaecol*. 55 (2), 123–130.
- Wang, G.S., Buttorff, C., Wilks, A., et al., 2022. Cannabis legalization and cannabis-involved pregnancy hospitalizations in Colorado. *Prev Med*. 156, 106993.
- Washington State Department of Health, 2022. Guidelines for Testing and Reporting Drug Exposed Newborns in Washington State. <http://2m2q501o69ol2wiszw2thkas-wpengine.netdna-ssl.com/wp-content/uploads/2016/09/2015-Guidelines-for-Testing-and-Reporting-Drug-Exposed-Newborns-in-Washington-State-1.pdf>. Accessed May 20, 2022.
- Woodruff, K., Scott, K.A., Roberts, S.C.M., 2021. Pregnant people's experiences discussing their cannabis use with prenatal care providers in a state with legalized cannabis. *Drug Alcohol Depend*. 227, 108998.

- Young-Wolff, K.C., Tucker, L.Y., Alexeeff, S., et al., 2017. Trends in self-reported and biochemically tested marijuana use among pregnant females in California from 2009–2016. *JAMA*. 318 (24), 2490–2491.
- Young-Wolff, K.C., Ray, G.T., Alexeeff, S.E., et al., 2021. Rates of prenatal Cannabis use among pregnant women before and during the COVID-19 pandemic. *JAMA*. 326 (17), 1745–1747.
- Zhao, G., Ford, E.S., Tsai, J., et al., 2012. Trends in health-related behavioral risk factors among pregnant women in the United States: 2001–2009. *J Womens Health (Larchmt)*. 21 (3), 255–263.